Kura Oncology, Inc (KURA) saw its loss widen to $7.53 million, or $0.39 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $6.63 million, or $0.36 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $7.65 million, compared with an operating loss of $7.04 million in the previous year period.
“We remain focused on operational execution, delivering on our portfolio and key milestones,” said Troy Wilson, Ph.D., J.D., President and Chief executive officer of Kura Oncology. “With tipifarnib, we are working to build upon the encouraging clinical activity we observed in our Phase 2 trial in HRAS mutant squamous cell head and neck cancers. We are also seeking to validate the potential novel biomarkers we identified in our Phase 2 trial in patients with PTCL, which we believe are associated with the initial activity we observed. We recently advanced KO-947, our second product candidate, into clinical testing, and we believe its profile and a substantial body of preclinical data make it a compelling therapeutic candidate. I’m pleased with our progress to advance multiple targeted programs aimed at addressing the urgent needs of cancer patients facing a poor prognosis and limited treatment options.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
